drugset / Trial / NCT00535860

Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis

NCT00535860

Phase 2 Completed 104 enrolled TransPharma Medical Eli Lilly and Company · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH \[1-34\] transdermal delivery in comparison to subcutaneous injection of rhPTH\[1-34\] following 3-month treatment in postmenopausal women with Osteoporosis

Timeline

Start
2008-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Other
Subject Teriparatide Protein / enzyme biologic 50 ug Other
Subject Teriparatide Protein / enzyme biologic 80 ug Other

Indications